severe cases – Page 6 – Communicable Diseases Research

Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis

백신 이전 시대의 연령별, 시기별, 지역별 코로나19 감염-치명률 변화: 체계적 분석

Article

Published on 2022-04-162022-09-11
Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 변종,

Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city

Research

Published on 2022-04-132022-10-05
Journal: Communications Medicine [Category] 변종, 치료기술, 치료법,

Timely treatment and higher compliance to traditional Chinese medicine: New influencing factors for reducing severe COVID-19 based on retrospective cohorts in 2020 and 2021

Research article

Published on 2022-04-012022-10-05
Journal: Pharmacological research [Category] COVID19(2023년), SARS, 변종, 치료법,

[키워드] addition adhere age Antibiotics antiviral medicine association calculated changed characterized Chinese cohort study cohorts collected Compliance Concomitant medication conditions conducted control limit COVID-19 patient COVID-19 patients diagnosed Diagnosis disease E-value effective Effectiveness enrolled Epidemic Factor Final hospital Hospitalization Hospitalized incidence independent risk factor initial symptom initial symptoms LCL less measure Mild mild COVID-19 Moderate COVID-19 multivariate logistic regression New objective outcome participant Patient predict Prognosis progressed proportion public health reduced reducing Result retrospective cohort retrospective cohort study sensitivity analysis Severe case severe cases severe COVID-19 Severity of disease Sex TCM The proportion to severe status Traditional Chinese medicine treat Treatment were used Wuhan
[DOI] 10.1016/j.phrs.2022.106174 [Article Type] Research article

Study of the effects of interferon β-1a on hospitalized patients with COVID-19: SBMU Taskforce on the COVIFERON study

입원한 COVID-19 환자에 대한 인터페론 β-1a의 효과 연구: COVIFERON 연구에 대한 SBMU 태스크포스

Article

Published on 2022-04-012022-09-11
Journal: Journal of medical virology [Category] Coronavirus, COVID19(2023년), SARS, 치료제,

[키워드] addition Antiviral conducted control group coronavirus disease Coronavirus disease 2019 COVID-19 died Effect Efficacy group hospital Hospital admission Hospital stay Hospitalized hospitalized COVID-19 patient hospitalized COVID-19 patients hospitalized patient hospitalized patients IFN-β1a immunomodulatory functions IMPROVE indicated innate immune system interferon Interferon β-1a interferons Iran median Mortality mortality rate no statistically significant difference outcome P-value Patient patients treated progression Randomized controlled trial regimen Retrospective study selected Severe case severe cases severe COVID-19 standard care standard treatment statistically statistically significant difference Tehran the interferon two group two groups
[DOI] 10.1002/jmv.27475 PMC 바로가기 [Article Type] Article

A Case Report for Using Methylprednisolone for Severe ARDS Caused by SARS-CoV-2 Delta Variant in a Pediatric Patient With Lennox-Gastaut Syndrome

Lennox-Gastaut 증후군이 있는 소아 환자에서 SARS-CoV-2 Delta 변이로 인한 중증 ARDS에 대한 Methylprednisolone 사용에 대한 증례 보고서

Case Reports

Published on 2022-03-142022-09-11
Journal: Journal of Korean medical science [Category] SARS, 변종,

[키워드] acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered ARDS B.1.617.2 caused children Comorbidities Comorbidity coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus disease-19 Coronavirus disease-19 (COVID-19) COVID-19 Delta End-Expiratory Pressure Expiratory Pressure extubation Fever high fever high-dose methylprednisolone hospital increased risk intractable Lennox-Gastaut Syndrome Methylprednisolone neurologic observation Oxygenation pandemic Pediatric patient Pediatric patients Positive end-expiratory pressure report reported required respiratory respiratory distress Respiratory distress syndrome SARS-CoV-2 SARS-CoV-2 delta Seizure Seizures severe acute respiratory syndrome Coronavirus severe ARDS Severe case severe cases severe COVID-19 syndrome the SARS-CoV-2 Tidal volume Treatment variant Volume
[DOI] 10.3346/jkms.2022.37.e82 PMC 바로가기 [Article Type] Case Reports

Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern

전염병 초기에 COVID-19 환자의 혈청은 우려의 변이에 대한 교차 중화의 제한된 증거를 보여줍니다

Article

Published on 2022-03-102022-09-11
Journal: Scientific Reports [Category] MERS, SARS, 변종, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Alpha antibody Antibody Response Antibody responses Beta chemokine chemokines clinical symptom Clinical symptoms Cohort cohort of patient Concentration coronavirus COVID-19 patient Critical critical state cross-neutralization cytokine Cytokines Delta detectable determine Evidence evidence of examined highlight Human human serum Immune status infected with SARS-CoV-2 Infection mechanism Mild mild to moderate moderate moderate infections moderate to severe Neutralizing antibodies neutralizing antibody pandemic pathogen Patient plasma Re-infection Recovered COVID-19 patients respiratory SARS-CoV-2 sera serum serum and plasma severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Severe case severe cases severe disease Severity of infection significantly increased variants variants of concern variety
[DOI] 10.1038/s41598-022-07960-4 PMC 바로가기 [Article Type] Article

SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity

특정 체액 면역이 없는 1차 항체 결핍 환자의 중증 및 치명적인 COVID-19에서 SARS-CoV-2 T 세포 반응

Article

Published on 2022-03-102022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, 치료기술, 치료법,

[키워드] activated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Analysis analyzed antibody autoantibodies autoantibody Blood CD169 CD4 cellular characterized clearance clinical disease Comorbidities Comorbidity convalescent convalescent plasma Convalescent plasma (CP) coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 cytokine deficiency detectable elevated examined excluded expression fatal COVID-19 flow cytometry healthy individuals heterogeneous humoral humoral immune response IgG Immunity immunodeficiency immunological immunological mechanism Inborn errors indicate innate immune response Innate immunity interferon interferons lack marker median monoclonal antibody Monocytes morbidity Mortality mucosal naïve nucleocapsid outcome Patient patients peptide peptide pool Peripheral blood persistence phenotype primary antibody primary antibody deficiency (PAD) Primary immunodeficiencies primary immunodeficiencies (PID) producing Prophylactic respiratory response Risk factors robust SARS-CoV-2 SARS-CoV-2 immunity SARS-CoV-2 RNA SARS-CoV-2 spike SARS-CoV-2 viral shedding seronegative severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Severe case severe cases severe COVID-19 patient SIGLEC1 Specific T cell T cell response T cells Treatment type I interferon type I interferon response type I interferons undetectable Viral viral clearance viral shedding with COVID-19
[DOI] 10.3389/fimmu.2022.840126 PMC 바로가기 [Article Type] Article

Activating endogenous resolution pathways by soluble epoxide hydrolase inhibitors for the management of COVID-19

COVID-19 관리를 위한 가용성 에폭사이드 가수분해효소 억제제에 의한 내인성 해결 경로 활성화

Review

Published on 2022-03-012022-09-11
Journal: Archiv der Pharmazie [Category] SARS, 비임상, 임상, 치료제,

COVID-19 in Children

어린이의 코로나19

Review

Published on 2022-03-012022-09-12
Journal: Infectious disease clinics of North America [Category] MERS, 진단,

Blocking TNF signaling may save lives in COVID-19 infection

TNF 신호를 차단하면 COVID-19 감염에서 생명을 구할 수 있습니다

Review

Published on 2022-03-012022-09-11
Journal: Molecular biology reports [Category] SARS, 바이오마커, 신약개발,

[키워드] activated Activation anti-TNF binding blocking Blood blood clotting burst cascades clinical trials conditions consequence COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 patient COVID-19 patients cytokine Cytokine storm Cytokines death downstream drug effort Evidence Factor heart failure high mortality Hope IFNγ IL-6 immune therapy insulin insulin resistance involved kinase kinases lung damage mechanism mediator Medicine monoclonal antibodies monoclonal antibody multiple organ failure NFkappaB NFkB Organ failure Other other conditions pathogenic Prevent pro-inflammatory cytokine pro-inflammatory cytokines provided receptor resulting selected Severe case severe cases the disease therapy TNF TNF signaling Treatment strategies treatment strategy Tumor tumor necrosis tumor necrosis factor Tumor Necrosis Factor (TNF). vaccination
[DOI] 10.1007/s11033-022-07166-x PMC 바로가기 [Article Type] Review